The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
Kraj
Maria
M
Department of Haematology Institute of Haematology and Blood Transfusion, ul. Chocimska 5, Warszawa, Poland. mkraj@ihit.waw.pl
Pogłód
Ryszard
R
Maj
Stanisław
S
Owczarska
Katarzyna
K
D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004002:Clodronic Acid / Q000009:adverse effects; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D015994:Incidence; D007571:Jaw Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced*; D000077268:Pamidronate; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D004002:Clodronic Acid; D000077211:Zoledronic Acid; D000077268:Pamidronate